茴拉西坦改善阿爾茨海默病小鼠認(rèn)知功能和增強(qiáng)突觸可塑性的機(jī)制探討
發(fā)布時(shí)間:2018-03-25 01:38
本文選題:阿爾茨海默病 切入點(diǎn):東莨菪堿 出處:《河北醫(yī)科大學(xué)》2017年碩士論文
【摘要】:目的:阿爾茨海默病(Alzheimer disease,AD)是最常見(jiàn)的老年期癡呆類型,其臨床特征表現(xiàn)為隱襲起病,進(jìn)行性的記憶和認(rèn)知功能減退,多伴有人格、精神異常,是年齡相關(guān)的神經(jīng)系統(tǒng)退行性疾病;病理學(xué)特征表現(xiàn)為β-淀粉樣蛋白(β-amyloid,Aβ)沉積于神經(jīng)元外形成大量老年斑(Senile plaques,SP)和神經(jīng)元內(nèi)形成以過(guò)度磷酸化的微管相關(guān)蛋白tau為主要成分的神經(jīng)原纖維纏結(jié)(Neurofibrillary tangles,NFTs),同時(shí)伴有膽堿能神經(jīng)元數(shù)量、突觸數(shù)量的明顯減少。迄今為止,AD的發(fā)病機(jī)制仍不是十分明確,當(dāng)前國(guó)內(nèi)外醫(yī)學(xué)界主要有以下幾種學(xué)說(shuō):膽堿能神經(jīng)損傷學(xué)說(shuō)、線粒體損傷學(xué)說(shuō)、氧化應(yīng)激學(xué)說(shuō)、遺傳與基因突變學(xué)說(shuō)等,但目前無(wú)一學(xué)說(shuō)能闡明其發(fā)病機(jī)制。東莨菪堿(scopolamine,SCO)是M型膽堿受體拮抗劑,可阻斷大腦皮層和海馬區(qū)乙酰膽堿對(duì)M受體的激動(dòng)作用,從而對(duì)記憶獲得產(chǎn)生阻抑效應(yīng),誘導(dǎo)癡呆,已經(jīng)被廣泛應(yīng)用在神經(jīng)營(yíng)養(yǎng)藥物的評(píng)估上。腹腔給藥3mg/Kg后可造成動(dòng)物記憶功能障礙。東莨菪堿用于誘導(dǎo)動(dòng)物記憶障礙模型具有簡(jiǎn)單、經(jīng)濟(jì)、方便等優(yōu)點(diǎn),故常應(yīng)用于抗AD活性化合物的初步篩選。茴拉西坦(aniracetam)作為γ-氨基丁酸的環(huán)化衍生物,為腦代謝增強(qiáng)藥,對(duì)于改善抑郁癥患者的癥狀方面具有長(zhǎng)期效果,同時(shí),茴拉西坦還有抗焦慮的作用。其主要作用機(jī)制可能是通過(guò)調(diào)節(jié)谷氨酸受體中的AMPA受體和類乙酰膽堿能系統(tǒng),但國(guó)內(nèi)尚未見(jiàn)將茴拉西坦應(yīng)用東莨菪堿致癡呆模型中,本實(shí)驗(yàn)以東莨菪堿致癡呆作為AD的模型,探討AMPA受體(Glu R1)、突觸可塑性蛋白的表達(dá)情況,并探討茴拉西坦是否可以通過(guò)激活谷氨酸受體磷酸化和增高突觸蛋白的表達(dá)來(lái)改善AD小鼠的認(rèn)知功能。方法:SPF級(jí)雄性BALB/c小鼠96只,全部動(dòng)物購(gòu)自北京華維通利華實(shí)驗(yàn)動(dòng)物技術(shù)有限公司,飼養(yǎng)于河北省人民醫(yī)院臨床研究中心動(dòng)物室內(nèi)。由動(dòng)物中心的飼養(yǎng)員管理,以標(biāo)準(zhǔn)的鼠糧及純凈的飲水飼養(yǎng)。將小鼠隨機(jī)分為6組:vehicle組(生理鹽水3mg/kg,vehicle group)、模型組(SCO 3mg/kg,SCO group)、低劑量組(SCO 3mg/kg+茴拉西坦40mg/kg,L-A group)、中劑量組(SCO 3mg/kg+茴拉西坦80mg/kg,M-A group)、高劑量組(SCO3mg/kg+茴拉西坦160mg/kg,H-A group)、石杉?jí)A甲組(SCO 3mg/kg+石杉?jí)A甲0.15mg/kg,Huper-A group),每組16只,SCO皮下注射日一次,連續(xù)給藥60天,茴拉西坦和石杉?jí)A甲在第50天灌胃給藥,均為日一次,連續(xù)給藥10天。造模完成后進(jìn)行新物體識(shí)別實(shí)驗(yàn),實(shí)驗(yàn)完成取小鼠海馬組織,采用Western blot蛋白分析法測(cè)定ERK1/2、p-ERK1/2、Glu R1、p-Glu R1Ser845、PSD-95、SYN在海馬組織蛋白表達(dá)量;采用RT-q PCR技術(shù)測(cè)定ERK1/2、Glu R1、PSD-95、SYN的m RNA表達(dá)量。采用免疫組化方法測(cè)定海馬組織PSD-95、SYN的陽(yáng)性細(xì)胞數(shù)。采用專用試劑盒檢測(cè)乙酰膽堿酯酶活性。結(jié)果:1茴拉西坦改善東莨菪堿引起的小鼠認(rèn)知功能下降與vehicle組相比,SCO組小鼠的認(rèn)知指數(shù)明顯降低(P0.01),這說(shuō)明東莨菪堿明顯降低了小鼠的認(rèn)知功能,造模成功。而經(jīng)茴拉西坦治療后,與SCO組相比,M-A和H-A組小鼠認(rèn)知指數(shù)均顯著升高(P0.01),說(shuō)明茴拉西坦可以改善小鼠的認(rèn)知功能。2茴拉西坦對(duì)突觸可塑性相關(guān)蛋白的影響2.1茴拉西坦激活東莨菪堿小鼠海馬ERK1/2蛋白表達(dá)磷酸化6組之間的ERK1/2蛋白表達(dá)水平?jīng)]有明顯統(tǒng)計(jì)學(xué)差異(P0.05);與vehicle組相比,SCO組小鼠海馬組織p-ERK1/2蛋白表達(dá)明顯下降(P0.01),說(shuō)明造模成功;而經(jīng)茴拉西坦治療后,與SCO組相比,M-A和H-A組海馬p-ERK1/2蛋白表達(dá)水平顯著升高(P0.01);陽(yáng)性對(duì)照組蛋白水平p-ERK1/2表達(dá)明顯升高(P0.01)。2.2茴拉西坦激活東莨菪堿小鼠海馬Glu R1蛋白表達(dá)磷酸化6組之間的Glu R1蛋白表達(dá)水平?jīng)]有明顯統(tǒng)計(jì)學(xué)差異(P0.05);與vehicle組相比,SCO組小鼠海馬組織p-Glu R1蛋白表達(dá)明顯下降(P0.01),說(shuō)明造模成功;而經(jīng)茴拉西坦治療后,與SCO組相比,H-A組海馬p-Glu R1蛋白表達(dá)水平顯著升高(P0.01);陽(yáng)性對(duì)照組蛋白水平p-Glu R1表達(dá)明顯升高(P0.01)。2.3茴拉西坦減輕東莨菪堿小鼠海馬突觸蛋白PSD-95、SYN表達(dá)的改變與vehicle組相比,SCO組小鼠海馬組織PSD-95、SYN蛋白表達(dá)明顯下降(P0.01,P0.01);而經(jīng)茴拉西坦治療后,與SCO組相比,L-A組海馬PSD-95、SYN蛋白水平均顯著升高(P0.01,P0.01);陽(yáng)性對(duì)照組PSD-95、SYN蛋白水平表達(dá)明顯升高(P0.01,P0.01)。免疫組織化學(xué)染色后可見(jiàn)蛋白表達(dá)水平的變化主要是在海馬CA1區(qū)。3茴拉西坦上調(diào)東莨菪堿小鼠海馬ERK1/2、Glu R1、SYN、PSD-95基因的表達(dá)與vehicle組相比,SCO組小鼠海馬組織ERK1/2、Glu R1、SYN、PSD-95基因表達(dá)均明顯下降(P0.01),而經(jīng)茴拉西坦治療后,與SCO組相比,M-A和H-A組海馬ERK1/2基因水平均顯著升高(P0.05,P0.01);與SCO組相比,H-A組海馬Glu R1基因水平均顯著升高(P0.01);與SCO組相比,L-A組海馬PSD-95、SYN基因水平均即顯著升高(P0.01、P0.01),陽(yáng)性對(duì)照組基因水平相應(yīng)基因表達(dá)均明顯升高(P0.01)。4乙酰膽堿酯酶活性測(cè)定結(jié)果與vehicle組相比,石杉?jí)A甲組乙酰膽堿酯酶活性明顯下降(P0.01),而SCO組乙酰膽堿酯酶活性與vehicle組相比差異沒(méi)有統(tǒng)計(jì)學(xué)意義(P0.05),同樣,茴拉西坦治療組對(duì)于乙酰膽堿酯酶活性的影響也沒(méi)有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:1茴拉西坦可以改善東莨菪堿引起的小鼠學(xué)習(xí)記憶能力下降。2茴拉西坦可以通過(guò)增加谷氨酸受體的磷酸化和突觸相關(guān)蛋白的表達(dá)來(lái)提高東莨菪堿小鼠的學(xué)習(xí)記憶能力。
[Abstract]:Objective: Alzheimer's disease (Alzheimer disease AD) is the most common type of senile dementia, the clinical features of insidious onset, progressive memory and cognitive dysfunction, accompanied by personality, mental disorders, is a neurodegenerative disease related to age; pathological features of beta amyloid protein (beta -amyloid and A beta) deposition in neurons formed outside a large number of senile plaques (Senile plaques, SP) and neuronal neurofibrillary tangle formation by hyperphosphorylation of microtubule associated protein tau as the main component (Neurofibrillary tangles, NFTs), accompanied by the number of cholinergic neurons, significantly reduced the number of synapses so far., the pathogenesis of AD is not very clear, the medical profession at home and abroad are mainly the following: the theory of cholinergic nerve damage theory, mitochondrial damage theory, oxidative stress theory, genetics and gene mutation The theory, but there is no theory can explain its pathogenesis. Scopolamine (scopolamine, SCO) is a type M cholinergic receptor antagonist, blocked acetylcholine in the cerebral cortex and hippocampus of M receptor agonist, which have inhibitory effect on memory access, induced dementia, has been widely used in the evaluation of neurotrophic drug. After intraperitoneal Administration of 3mg/Kg can cause memory impairment induced by scopolamine in animal. The animal model of memory disorder is simple, economic, convenient, preliminary screening is often used in anti AD active compounds. Lacita fennel (aniracetam) as ring derivatives of gamma aminobutyric acid, brain metabolism drugs, has long the effect in improving the symptoms of depression at the same time, Ra Laci Staw and anti anxiety. The main mechanism may be through the regulation of glutamate receptor in AMPA receptor And the cholinergic system, but there is no dementia model induced by scopolamine in the application of Ra Laci Staw, in this experiment, scopolamine induced dementia as the AD model, to investigate the AMPA receptor (Glu R1), the expression of synaptic plasticity protein, and to explore the cognitive function of Ra Laci Staw whether by expression of activation of glutamate receptor phosphorylation and increased synaptic to improve the AD protein in mice. Methods: SPF male BALB/c 96 mice all animal was purchased from Beijing Hua Lihua Experimental Animal Technology Co. Ltd., raised in Hebei People's Hospital clinical research laboratory animal research center. By the breeder management of Animal Center, feeding with the standard rat food and clean drinking water. The mice were randomly divided into into 6 groups: group vehicle (normal saline 3mg/kg, vehicle group), model group (SCO 3mg/kg, SCO group), low dose group (SCO 3mg/kg+ 40mg/kg L-A group La zetham fennel,), in Dose group (SCO 3mg/kg+ 80mg/kg M-A group aniracetam, high dose group (SCO3mg/kg+), aniracetam 160mg/kg, H-A group), huperzine a group (SCO 3mg/kg+ huperzine 0.15mg/kg, Huper-A group), 16 rats in each group, SCO subcutaneous injection once a day, continuous administration for 60 days, fennel Tracy Tanzania and huperzine A in fiftieth days were administered orally, once a day, continuous administration for 10 days. After modeling the new object recognition experiment, experiment the mice hippocampus, determination of ERK1/2, analysis by using the method of Western blot protein p-ERK1/2, Glu R1, p-Glu R1Ser845, PSD-95, expression SYN in hippocampus protein; Determination of ERK1/2, using RT-q PCR technology Glu R1, PSD-95, RNA SYN. The expression of M was measured by immunohistochemical method of PSD-95 in the hippocampus, the number of SYN positive cells. Acetylcholinesterase activity was measured by special kit. Results: 1 aniracetam scopolamine induced small In cognitive decline compared with the vehicle group, cognitive index in group SCO were significantly lower (P0.01), indicating that scopolamine significantly reduces the cognitive function in mice, animal model. By Lacita fennel after treatment, compared with group SCO, M-A and H-A group were significantly elevated both cognitive index (P0.01), description effect of aniracetam can improve the cognitive function of.2 mice Lacita fennel proteins related to synaptic plasticity 2.1 aniracetam activation of scopolamine in mice ERK1/2 protein expression in hippocampus phosphorylation between the 6 groups in the expression level of ERK1/2 protein had no obvious statistical difference (P0.05); compared with vehicle group, the expression of SCO p-ERK1/2 protein in the hippocampus of mice significantly decreased (P0.01), indicating that the model was successful; by aniracetam after treatment, compared with the SCO group, the expression level of M-A and p-ERK1/2 protein in hippocampus of H-A group increased significantly (P0.01); the protein level of p-ERK1/ in the positive control group 2 expression was significantly increased (P0.01).2.2 aniracetam activation of scopolamine in mice hippocampal Glu protein expression of R1 phosphorylation of Glu between the 6 groups R1 protein expression level showed no statistically significant differences (P0.05); compared with vehicle group, SCO p-Glu expression of R1 protein in hippocampus of mice decreased significantly (P0.01), indicating that the model was successful; and by aniracetam after treatment, compared with the SCO group, the expression level of H-A in group p-Glu significantly increased R1 protein (P0.01) positive control group; p-Glu protein level significantly increased the expression of R1 (P0.01).2.3 aniracetam reduce mouse hippocampal synaptic protein PSD-95 induced by scopolamine, the change of SYN expression compared with vehicle group, hippocampus SCO mice in group PSD-95, SYN protein expression was significantly decreased (P0.01, P0.01); and by aniracetam after treatment, compared with the SCO group, L-A group, PSD-95 in hippocampal SYN protein levels were significantly increased (P0.01, P0.01); the positive control group PSD-95, SYN protein The level of expression was significantly increased (P0.01, P0.01). Immunohistochemical staining showed protein expression level changes mainly in the hippocampal CA1 region.3 upregulation of scopolamine in mice hippocampus ERK1/2 Hui Lacita, Glu R1, SYN, PSD-95 gene expression compared with vehicle group, SCO group of mice sea horse tissue ERK1/2, Glu R1, SYN, PSD-95 gene expression decreased significantly (P0.01), and by aniracetam after treatment, compared with the SCO group, M-A group and H-A ERK1/2 gene in the hippocampus were significantly increased (P0.05, P0.01); compared with SCO group, the level of H-A group in hippocampus Glu of R1 gene was significantly elevated (P0.01); compared with the SCO group. In group L-A, PSD-95, SYN gene levels were increased significantly (P0.01, P0.01), the corresponding gene expression level of gene positive control group were significantly higher (P0.01).4 determination of acetylcholinesterase activity compared with vehicle group, huperzine a group of acetylcholinesterase activity decreased obviously (P0.0 1), and SCO group acetylcholinesterase activity compared with vehicle group, the difference was not statistically significant (P0.05). Similarly, Ra Laci Staw treatment group effect on acetylcholinesterase activity was also not statistically significant (P0.05). Conclusion: 1 aniracetam induced by scopolamine can improve the learning and memory ability of mice decreased.2 aniracetam can improve learning and memory the ability of scopolamine in mice by increasing the expression of synapse associated protein phosphorylation and glutamate receptors.
【學(xué)位授予單位】:河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2017
【分類號(hào)】:R749.16
【參考文獻(xiàn)】
相關(guān)期刊論文 前2條
1 杜青;馮珍;;N-甲基-D-天冬氨酸受體與神經(jīng)系統(tǒng)疾病關(guān)系的研究進(jìn)展[J];中國(guó)康復(fù)理論與實(shí)踐;2016年10期
2 商秀麗,薛一雪,蔡葵,徐萬(wàn)鵬,高敬偉;阿爾茨海默病大鼠海馬N-甲基天冬氨酸受體和絲裂酶原激活蛋白激酶的表達(dá)[J];解剖學(xué)報(bào);2005年03期
,本文編號(hào):1660997
本文鏈接:http://www.sikaile.net/shoufeilunwen/mpalunwen/1660997.html
最近更新
教材專著